Overview
Akeega is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic castration-resistant prostate cancer (mCRPC) who have a BRCA mutation (a change in BRCA1 or BRCA2…

Overview
Camcevi ETM is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with advanced prostate cancer. Camcevi ETM is also known by its drug name, leuprolide.

Leuprolide is a…

Overview
Camcevi Point-Lok Needle is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with advanced prostate cancer. The prescription includes a prefilled syringe with a separate needle…

Overview
Camcevi SurGuard 3 Safety Needle is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with advanced prostate cancer. The prescription includes a prefilled syringe called the…

Overview
Casodex is approved by the U.S. Food and Drug Administration (FDA) for the treatment of stage D2 metastatic prostate cancer. It is prescribed as part of combination therapy with a luteinizing hormone-releasing…

Overview
Eligard is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced prostate cancer. It is a form of androgen deprivation therapy (ADT) that reduces testosterone levels to slow the…

Overview
Erleada is approved by the U.S. Food and Drug Administration (FDA) to treat metastatic castration-sensitive prostate cancer (mCSPC) and nonmetastatic castration-resistant prostate cancer (nmCSPC). When taking…

Overview
Firmagon is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced prostate cancer. It is used as a form of androgen deprivation therapy (ADT) to reduce testosterone levels, which…

Overview
Lupron Depot is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced prostate cancer. It is a form of androgen deprivation therapy (ADT) that helps lower testosterone levels…

Overview
Lynparza is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic castration-resistant prostate cancer (mCRPC) that has either germline or somatic mutations…